Category Archives: Treatment

Leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients: A literature review

2015

INTRODUCTION: After the onset of highly active antiretroviral therapy (HAART), some HIV-infected patients present a severe inflammation in response to a latent or a previously treated opportunistic pathogen termed immune...

Viral suppression in adolescents on antiretroviral treatment: Review of the literature and critical appraisal of methodological challenges

2016

OBJECTIVE: Medication adherence is often sub-optimal for adolescents with HIV, and establishing correct weight-based antiretroviral therapy dosing is difficult, contributing to virological failure. This review aimed to determine the proportion...

HIV-associated oral lesions as an indicator for HAART failure: A review

2012

INTRODUCTION: HIV-associated oral lesions have been used as clinical indicators of HIV infection and/or HIV-disease progression. It is well established that there is a significant reduction in the incidence of...

Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: A systematic review and meta-analysis of 114 studies with up to 144 weeks’ follow-up

2014

BACKGROUND: A comprehensive assessment of initial HIV-1 treatment success may inform study design and treatment guidelines. METHODS: Group-based, systematic review and meta-analysis of initial antiretroviral therapy studies, in adults, of...

Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: A meta-analysis of randomized controlled trials

2015

Lopinavir/ritonavir (LPV/r) is the first ritonavir-boosted protease-inhibitor used in second-line anti-retroviral treatment (ART) in resource-limited regions. To evaluate the efficacy and safety outcomes of LPV/r in treatment-naive and -experienced HIV-infected...

New approaches to antiretroviral drug delivery: Challenges and opportunities associated with the use of long-acting injectable agents

2014

Research on improved treatment of HIV infection and pre-exposure prophylaxis continues. Poor adherence to treatment is the critical risk factor for virological failure and resistance development, and long-acting formulations of...

Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: A systematic review and meta-analysis of randomized trials

2015

INTRODUCTION: Efavirenz (EFV) is widely used for the treatment of antiretroviral-naive HIV-positive individuals, but there are concerns about the risk of adverse neuropsychiatric events. We systematically reviewed the safety of...

Growth reconstitution following antiretroviral therapy and nutritional supplementation: Systematic review and meta-analysis

2015

OBJECTIVE: As antiretroviral therapy (ART) expands for HIV-infected children, it is important to determine its impact on growth. We quantified growth and its determinants following ART in resource-limited (RLS) and...

The HIV care cascade before, during, and after incarceration: A systematic review and data synthesis

2015

We conducted a systematic literature review of the data on HIV testing, engagement in care, and treatment in incarcerated persons, and estimated the care cascade in this group. We identified...

Factors associated with antiretroviral treatment uptake and adherence: A review. Perspectives from Australia, Canada, and the United Kingdom

2015

International focus on reducing onward HIV transmission emphasizes the need for routine HIV testing and early uptake of antiretroviral treatment (ART). Strategic targets have been set for 2020 to achieve...

Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis

2006

BACKGROUND: We incorporated the latest available information to evaluate the net benefit of using resistance testing in HIV-infected patients with virological failure. METHODS: Meta-analysis of randomized controlled trials comparing the...

Cobicistat: A new opportunity in the treatment of HIV disease?

2014

INTRODUCTION: Cobicistat (Cobi), a selective novel CYP3A4 inhibitor, is an orally administered, non-antiretroviral pharmacokinetic enhancer which boosts the plasma levels of several drugs, including HIV-1 protease inhibitors and the integrase...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!